Company news

IceCure Medical Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

April 2, 2024

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

April 1, 2024

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

March 18, 2024

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

March 11, 2024

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

January 29, 2024

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

January 11, 2024

IceCure's ProSense® Deepens Regulatory Approval in India

November 28, 2023

IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate

November 27, 2023

IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights

November 14, 2023

IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer

November 14, 2023

Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%

October 4, 2023

Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate

October 1, 2023

IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer

September 19, 2023

IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil

September 4, 2023

IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

August 27, 2023

IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum

August 13, 2023

IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023

August 6, 2023

Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System

July 23, 2023

IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales

July 16, 2023

IceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country

May 30, 2023

IceCure Medical Reports First Quarter 2023 Financial & Operational Results

May 21, 2023

IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange

April 18, 2023

IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes

March 27, 2023

IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights

February 8, 2023

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems

January 17, 2023

IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

December 22, 2022

IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

December 20, 2022

IceCure Medical Ltd. Announces Proposed Public Offering

December 19, 2022

IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results

December 18, 2022

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

December 5, 2022

IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights

December 4, 2022

IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

November 27, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

November 7, 2022

IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month

October 25, 2022

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

October 18, 2022

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil

October 10, 2022

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

August 28, 2022

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights

August 14, 2022

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

July 24, 2022

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

June 12, 2022

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

June 8, 2022

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights

May 17, 2022

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

May 10, 2022

IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology

April 26, 2022

IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results

January 30, 2022

IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option

December 12, 2021

IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering

December 8, 2021

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

November 28, 2021

IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments

November 22, 2021

IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSense™

October 31, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.